Making all naloxone products available OTC in the US could limit, not expand access to the opioid overdose treatment, according to comments submitted before a panel of Food and Drug Administration advisors discusses the first naloxone switch proposal, for a nasal spray.
The American Society of Anestiologists and attorney Scott Lassman both made clear in comments, submitted to the docket for a...







